Mar 23, 2017: C4 Therapeutics and Calico Enter Strategic Partnership to Discover Novel Therapeutics Based on Targeted Protein Degradation
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif. – Mar. 23, 2017 – C4 Therapeutics (C4T) and Calico today announced a five-year collaboration to discover, develop and commercialize therapies for treating diseases of aging, including cancer.
Under the terms of the agreement, the parties will leverage C4T’s expertise and capabilities in targeted protein degradation to jointly discover and advance small molecule protein degraders as therapeutic agents to remove certain disease-causing proteins. The partnership will pursue preclinical research and Calico will be responsible for subsequent clinical development and commercialization of resulting products that may emerge from the collaboration.
“We are thrilled to have Calico as partners in pioneering novel therapeutics based on targeted protein degradation,” said Andrew Phillips, President and Chief Scientific Officer of C4 Therapeutics. “Calico’s leadership team has a long record of innovation and our combined efforts are aimed at bringing forward new options for patients affected by devastating diseases such as cancer.”
“We know from decades of translational research that it can be incredibly challenging to find effective pharmacologic inhibitors of many of the biologically well-validated targets, particularly in cancer,” said Hal Barron, President of Research and Development at Calico. “Through the alternative strategy of specifically targeting such proteins for degradation, we believe we have the opportunity to identify promising new therapeutics in cancer and in other diseases as well. We’re looking forward to collaborating with C4T’s scientists and applying their protein degradation technology to the discovery and development of effective new treatments.”
About C4 Therapeutics
C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. This distinctive mechanism provides new opportunities to target traditionally difficult-to-treat diseases and diseases plagued by drug resistance. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
Calico (Calico Life Sciences LLC) is an Alphabet-funded research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. Calico will use that knowledge to devise interventions that enable people to lead longer and healthier lives. To learn more about Calico, visit www.calicolabs.com.
Nov 17, 2016: C4 Therapeutics Announces World-Class Scientific Advisory Board With Expertise in Therapeutics and the Ubiquitin-Proteasome System
CAMBRIDGE, Mass. – November 17, 2016 – C4 Therapeutics (C4T) today announced Ken Anderson, M.D., Nathanael Gray, Ph. D., Christopher Kirk, Ph. D. and Eric Fischer, Ph. D as the members of its Scientific Advisory Board (SAB).
“We are thrilled to have Ken, Nathanael, Chris, and Eric play an important role as our advisors at C4T,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Their world-renowned expertise in clinical oncology, drug discovery and development, and the basic-science of the ubiquitin-proteasome system will be invaluable as we both advance drug candidates toward the clinic and develop new tools and technologies that keep C4T at the cutting edge.”
The inaugural members of the C4 Therapeutics scientific advisory board include:
Ken Anderson, M.D.
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. His research has pioneered understanding of the tumor microenvironment in multiple myeloma, and he has played an extensive role in the development and approval of numerous new treatments for myeloma patients. His research and impact on patient outcomes has been widely recognized including the ASH William Dameshek Prize, AACR Joseph Burchenal Award, ASCO David Karnofsky Award, and the ACS Medal of Honor in Science.
Dr. Anderson received his M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. He is a member of the Institute of Medicine of the National Academy of Sciences, served as President of the International Myeloma Society, and is President-elect of the American Society of Hematology.
Nathanael Gray, Ph.D.
Dr. Gray is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and an Investigator at Dana-Farber Cancer Institute. Previously, he was a Director of Biological Chemistry at the Genomics Institute of the Novartis Research Foundation. His research focuses on the discovery of small molecules that impact biological pathways important in cancer. These efforts have produced numerous first-in-class kinase inhibitors that have become widely used to understand complex biology and have also inspired drug discovery programs.
Dr. Gray’s research has been recognized by many awards including the Meyenburg Cancer Research Award, the American Chemical Society Award for Outstanding Research in Biological Chemistry, and the AACR Award for Team Science. Dr. Gray received his Ph.D. from the University of California at Berkeley.
Christopher Kirk, Ph.D.
Dr. Chris Kirk is Co-Founder, President, and Chief Scientific Officer of Kezar Life Sciences. Prior to Kezar, Dr. Kirk was the Vice President of Research at Onyx Pharmaceuticals, where he played a key role in the discovery and development of two proteasome inhibitors, carfilzomib (KYPROLIS™), currently approved for the treatment of multiple myeloma, and oprozomib, currently in Phase II clinical trials.
Dr. Kirk is a co-inventor on over 30 patents and has authored more than 45 publications in leading journals including Cell, Nature Medicine, and Nature Reviews. Dr. Kirk received his B.S. from the University of California, Davis and his Ph.D. in cellular and molecular biology from the University of Michigan.
Eric Fischer, Ph.D.
Dr. Fischer is an Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on the use of structural biology, cell biology, and biochemical approaches to develop an intimate understanding of the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in cancer and ultimately leverage this understanding for the development of novel therapeutic strategies.
Dr. Fischer has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide. Dr. Fischer received his B.Sc. in molecular biology and M.Sc. in structural biology from the University of Basel and his Ph.D. in structural biology from the Friedrich Miescher Institute in Switzerland.
About C4 Therapeutics
C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. This distinctive mechanism provides new opportunities to target traditionally difficult-to-treat diseases and diseases plagued by drug resistance.
More information about C4 Therapeutics is available at www.C4Therapeutics.com.
Sep 22, 2016: C4 Therapeutics Appoints Andrea Armstrong as Chief Administrative Officer
CAMBRIDGE, Mass. – September 22, 2016 – C4 Therapeutics (C4T) today announced that Andrea Armstrong has been promoted to Chief Administrative Officer. She joined C4T as a human resources consultant in January, 2016 and transitioned to full-time as the Senior Vice President of Human Resources in June, 2016. Ms. Armstrong has led the human resources function with a focus on talent acquisition efforts and will now also assume responsibility for facilities and laboratory operations, environmental health and safety, IT and office management, and internal communications.
“Andrea has been integral to the growth of C4T to this point,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “In addition to Andrea’s talents in human resources, her extensive organizational development and operational experience will bring much to our next phase of growth. I look forward to working with her in this expanded role.” read more...
Sep 19, 2016: FierceBiotech names C4 Therapeutics as one of its “Fierce 15” Biotech Companies of 2016
CAMBRIDGE, Mass. – September 19, 2016 – C4 Therapeutics (C4T) today announced that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“We are humbled to be named a 2016 Fierce 15 company,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Since launching the company in January this year, the C4T team has rapidly built a world class science organization, made tremendous headway on internal projects, and moved forward with our partner Roche. The Fierce15 award is a testament to this momentum, and also to the potential of our approach to targeted protein degradation for developing transformative new therapeutics.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. read more...
Sep 14, 2016: C4 Therapeutics Appoints Andrew Phillips, Ph.D. as President and Chief Scientific Officer
CAMBRIDGE, Mass. – September 14, 2016 – C4 Therapeutics (C4T) today announced that Andrew Phillips, Ph.D. has been promoted to President and Chief Scientific Officer, reporting directly to Executive Chairman Marc Cohen. The Company also announced Jason Fisherman, M.D. has resigned as President/CEO and as a member of the Board of Directors to pursue other professional opportunities. Since joining C4T as Chief Scientific Officer in January 2016, Dr. Phillips has been leading the development of Targeted Protein Degradation (TPD) therapeutics based on the Company’s groundbreaking Degronimid™ platform.
“Andy has played a key role in C4T’s rapid growth since joining us earlier this year. He has been instrumental in the recruitment of world-class scientific talent, the development of a robust internal drug discovery portfolio, and the initiation of our strategic alliance with Roche. C4T is a science-driven company and Andy is ideally suited to lead the Company in the development of therapeutics in his expanded role as President and Chief Scientific Officer,” said Marc Cohen, Co-Founder and Executive Chairman of C4 Therapeutics. “We thank Jason for his leadership and contribution to the C4T launch and wish him the best as he pursues other endeavors.”
Prior to joining C4T, Dr. Phillips was Senior Director, Center for Development of Therapeutics at the Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships. Previously, he was a Full Professor of Chemistry at Yale University, where he received the ACS Cope Scholar Award for his research accomplishments, which included the development of small molecules aimed at modulating ‘undruggable’ targets. Prior to this, he was a Full Professor of Chemistry and Biochemistry at the University of Colorado at Boulder, where his efforts in complex molecule synthesis and targeting protein-protein interactions garnered a number of awards, including an Alfred P. Sloan Research Fellowship, an Eli Lilly Grantee Award, and a National Science Foundation CAREER Award.
Dr. Phillips received a B.Sc. (Hons) in biochemistry and a Ph.D. in biochemistry and chemistry from the University of Canterbury in New Zealand and completed a postdoctoral fellowship in organic chemistry at the University of Pittsburgh. read more...
Sep 2, 2016: C4 Therapeutics Completes Core Scientific Leadership Team to Accelerate the Discovery of Novel Therapeutics for Targeted Protein
Highlights Leadership in Biology, Chemistry, Discovery Sciences, Translational Sciences
and Alliance Management
Cambridge, Mass. – September 2, 2016 - C4 Therapeutics (C4T) today announced details of the leadership team recruited to develop a new class of broadly applicable small molecule drugs for degrading disease-relevant proteins for therapeutic benefit. The leadership team includes Isabel Chiu, Ph.D. as Senior Vice President of Translational Sciences and Alliance Management, Stewart Fisher, Ph.D. as Senior Vice President of Discovery Sciences, Tim Heffernan, Ph.D., as Senior Vice President of Biology, and Christopher Nasveschuk, Ph.D. as Vice President of Chemistry.
“Isabel, Stew, Tim, and Chris are recognized leaders in translational research, biochemistry and discovery sciences, cancer biology, and chemistry. Over the past 6 months they have added much momentum to our science and capabilities build. Their deep expertise in drug discovery will continue to advance our development of first-in-class Degronimid™ molecules for the treatment of cancer and other life-threatening and life-impairing diseases,” said Andy Phillips, Ph.D., Chief Scientific Officer of C4 Therapeutics.
Dr. Chiu most recently served as Vice President of Translational and Clinical Science at Enumeral Biomedical and was previously Vice President of Translational Research at AVEO Oncology. In these roles, Dr. Chiu was responsible for target and biomarker discovery, validation, preclinical development, and played key leadership roles in strategic partnerships. She also contributed to the development of numerous small molecule and antibody programs in the clinic through external collaborations and internal pipelines. She received her postdoctoral training at Johns Hopkins Medical School, holds a Ph.D. in biology from MIT, and a B.A. in biochemistry from Brandeis University.
Dr. Fisher previously held senior leadership roles at the Broad Institute and AstraZeneca across target validation, drug discovery, and clinical candidate support. Dr. Fisher started his career at Hoffmann-La Roche after completing an NIH Postdoctoral Fellowship at Harvard Medical School. He holds a Ph.D. in organic chemistry from the California Institute of Technology and a B.A. in chemistry from the University of Vermont.
Prior to joining C4 Therapeutics, Dr. Heffernan held positions of increasing responsibility at the Institute for Applied Cancer Science at MD Anderson Cancer Center. He most recently served as Co-Director and Head of Drug Development, where he managed drug discovery and research programs from target identification through preclinical development. Previously, Dr. Heffernan led target discovery at the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. He holds a Ph.D. in cell and molecular pathology from the University of North Carolina at Chapel Hill and performed his postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School.
Dr. Nasveschuk joined C4 Therapeutics from the Broad Institute, where he led a group of medicinal chemists in projects in the cancer, metabolism, and autophagy disease areas at the Center for the Development of Therapeutics. Prior to Broad, Dr. Nasveschuk was an integral member of the team at Constellation Pharmaceuticals where he co-invented the EZH2 inhibitor CPI-1205 and helped to discover and develop the BET inhibitor CPI-0610. He holds a Ph.D. in organic chemistry from Colorado State University and a B.S. in chemistry from Middlebury College. read more...
Feb 22, 2016: C4 Therapeutics Appoints Thomas E. Needham, Jr., MBA as Chief Business Officer
Cambridge, Mass. – February 17, 2016 - C4 Therapeutics today announced the appointment of Thomas E. Needham, Jr., MBA, to the position of Chief Business Officer. Mr. Needham joins with over 20 years of experience in venture capital, business development, corporate strategy and executive management responsibilities in public and private biotechnology companies. In this new role, Mr. Needham will lead C4 Therapeutics’ corporate and business development, finance, legal and corporate communications functions. (Read Full Press Release).
Feb 2, 2016: Informa Pharma Insights Releases Interview of C4 Therapeutics Executive Chairman, Marc Cohen
San Francisco, CA. - January 12, 2016 - Fresh from announcing the creation of the company, a USD 75 million series A financing, and a deal with Roche which has a potential bio dollar value north of USD 750 million, C4 Therapeutics co-founder and executive chairman Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works. (Watch the Interview)
Feb 2, 2016: C4 Therapeutics Appoints Andrew Phillips, PhD. as Chief Scientific Officer
Cambridge, MA. - February 2, 2016 - C4 Therapeutics today announced the appointment of Andrew Phillips, Ph.D. as Chief Scientific Officer. Dr. Phillips joins from the Broad Institute of MIT and Harvard and will lead C4 Therapeutics’ research efforts and the development of proprietary therapeutics based on the Company’s groundbreaking Degronimid™ platform. (Read full press release)
Jan 7, 2016: C4 Therapeutics Enters Strategic Drug Discovery Collaboration with Roche Pharma in the Promising New Field of Targeted Protein Degradation
Cambridge, MA. - January 7, 2016 - C4 Therapeutics today announced that they will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid™ technology. C4’s Degronimids represent a new class of small molecules, TPD therapeutics, which target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the ubiquitin/proteasome system (UPS). (Read full press release)
Jan 7, 2016: Dana-Farber Spinout Grabs $75m, Plus large Roche Deal, To Craft New Form of Cancer Drug
Cambridge, MA. - January 7, 2016 - Billions of dollars have been made from cancer drugs that inhibit the ubiquitin-proteasome system, otherwise known as the cellular garbage dump. By turning off the cell’s garbage disposal system, these drugs enable proteins to build up to a point where malignant cells commit suicide. Clever as these drugs are, tumors usually find a way to mutate and develop resistance. (Read the full article)
Jan 7, 2016: Tech Mogul, Patriots Owner Lavish $75M on Dana-Farber Startup
Cambridge, MA. - January 7, 2016 -When physician-scientist Jay Bradner left the Dana-Farber Cancer Institute last year, he left behind some key scientific work that had already intrigued a group of investors. Bradner is now president of the Novartis Institutes for Biomedical Research, but his Dana-Farber research continued in the hands of others. It’s now the basis of a new startup called C4 Therapeutics that debuts today with a hefty financing round. (Read full article)
Jan 6, 2016: Dana-Farber Spinout Tackles Protein Degradation with $75M round, $750M Roche Deal in hand.
Cambridge, MA. - January 6, 2016 - While Jay Bradner is transitioning to head up the Novartis Institutes for BioMedical Research, some of the most important work he did at the prestigious Dana-Farber Cancer Institute is now advancing toward the clinic at a nearby startup that's launching today with a hefty $73 million round and a $750 million partnership with Roche ($RHHBY). (Read full article)
May 21, 2015: New Chemical Technology Boosts Potency of Targeted Cancer Therapy
Boston, MA. - May 21, 2015 -n work that heralds a new, more potent form of targeted therapy for cancer, Dana-Farber Cancer Institute scientists have devised a chemical technology that doesn’t just disable malevolent proteins in tumor cells, as current agents do, but destroys them.
For an explanation of degronimid™ technology, read the full article here in the DFCI Newsroom.